

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

*PC 02/20**315911*

<p>Licensee</p> <p>1. Howard Regional Health System</p> <p>2. 3500 S. La Fountain Street Kokomo, IN 46902</p>	<p>In accordance with the letter dated November 30, 2006, and facsimiles dated February 20, 2007 and February 21, 2007,</p> <p>3. License number 13-13028-02 is amended in its entirety to read as follows:</p> <p>4. Expiration date May 31, 2014</p> <p>5. Docket No. 030-13342 Reference No.</p>
---	--

- | | | |
|--|---|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed (not to exceed 2 curies of iodine-131)</p> |
|--|---|--|
9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 3500 South La Fountain Street, Kokomo, Indiana.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
13-13028-02

Docket or Reference Number
030-13342

Amendment No. 28

11. Radiation Safety Officer for this license is Rik Stephens, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical uses:

<u>Authorized User</u>	<u>Material and Use</u>
James M. Scheffler, M.D.	10 CFR 35.200
Shamim Dada, M.D.	10 CFR 35.100, 35.200 and 35.300.
Peter Nechay, M.D.	10 CFR 35.200.
Brett A. Hagedorn, M.D.	10 CFR 35.100, 35.200 and 35.300.
John Rock, M.D.	10 CFR 35.100 and 35.200.
Rik Stephens, M.D.	10 CFR 35.100, 35.200 and 35.300.
James C. Wehrenberg, M.D.	10 CFR 35.100 and 35.200.
James A. Arata, M.D.	10 CFR 35.100, 35.200 and 35.300.
David B. Janizek, M.D.	10 CFR 35.100, 35.200 and 35.300.
Christine Anne Tremper, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the treatment of hyperthyroidism).
Randall J. Phillips, M.D.	10 CFR 35.100, 35.200 and 35.300.
John Pasalich, M.D.	10 CFR 35.100, 35.200 and 35.300.
Stephen R. Phillip, M.D.	10 CFR 35.100, 35.200 and 35.300.
Marc Thomas, M.D.	10 CFR 35.100, 35.200 and 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-13028-02Docket or Reference Number
030-13342

Amendment No. 28

Authorized UserMaterial and Use

Diane D. Daly, M.D.	10 CFR 35.100, 35.200 and 35.300.
John L. Bormann, M.D.	10 CFR 35.100, 35.200 and 35.300.
Michael E. Parker, M.D.	10 CFR 35.100, 35.200 and 35.300.
Pamela Lee Strange, M.D.	10 CFR 35.100, 35.200 and 35.300.
Michael W. Tanksley, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding thyroid carcinoma therapy).
Joseph R. Decamp, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the treatment of hyperthyroidism).
John R. Kim, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Frederick N. Vandeman, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Andre Byard Stovall, M.D.	10 CFR 35.100, 35.200 and 35.300.
Christopher Michael Kowalski, M.D.	10 CFR 35.100 and 35.200.
Gina W. Hook, M.D.	10 CFR 35.100 and 35.200.
Richard W. Sibley, M.D.	10 CFR 35.100, 35.200 and 35.300.
Dakshesh S. Patel, M.D.	10 CFR 35.100 and 35.200.
Eric V. Heatwole, M.D.	10 CFR 35.100 and 35.200.
Shilpa Kashyap, M.D.	10 CFR 35.100 and 35.200.
Shawn Johnson, M.D.	10 CFR 35.100, 35.200 and 35.300.

13. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Materials."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-13028-02


Docket or Reference Number

030-13342

Amendment No. 28

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated April 20, 2003; and
- B. Letter dated March 5, 2006, July 27, 2006, and November 30, 2006, and ;
- C. Facsimiles dated February 20, 2007, and February 21, 2007.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date FEB 22 2007

By

William P. Reichhold
Materials Licensing Branch
Region III